Klaira 28 tablets — Made in Germany — Free Delivery

Product description

Klaira tablets are used for the following indications:

• oral contraception;
• treatment of heavy menstrual bleeding in women without organic pathology, who were prescribed oral contraception.

Structure

The active ingredients are estradiol valerate, dienogest.

Each calendar pack (28 film-coated tablets) contains:

2 dark yellow tablets, each containing 3 mg estradiol valerate;

5 red tablets, each containing 2 mg estradiol valerate and 2 mg dienogest;

17 light yellow tablets, each containing 2 mg estradiol valerate and 3 mg dienogest;

2 dark red tablets, each containing 1 mg estradiol valerate;

2 white placebo pills.

Excipients: lactose monohydrate, corn starch, pregelatinized starch, povidone, magnesium stearate, hypromellose, macrogol 6000, talc, titanium dioxide (E 171), iron oxide yellow (E172) or iron oxide red (E172).

Placebo: lactose monohydrate, corn starch, povidone, magnesium stearate, hypromellose, talc, titanium dioxide (E 171).

Contraindications

You should not use CHC in the presence of any of the conditions listed below. If any of them develops for the first time during the use of CHC, you must immediately stop taking the preparation.

The presence or risk of developing venous thromboembolism (VTE):

• the presence of venous thromboembolism at the present time (during anticoagulant therapy) or in history (for example, deep vein thrombosis (DVT), pulmonary embolism (PE);
• known hereditary or acquired tendency to venous thromboembolism, such as resistance to activated protein C (including factor V Leiden mutation), antithrombin-III deficiency, protein C deficiency, protein S deficiency;
• large surgical interventions with prolonged immobilization;
• high risk of venous thromboembolism due to the presence of multiple risk factors.

Presence or risk of developing arterial thromboembolism (ATE):

• arterial thromboembolism: a history of arterial thromboembolism (eg myocardial infarction) or prodromal symptoms (eg angina pectoris);
• disorders of cerebral circulation: a history of stroke, the presence of prodromal symptoms (for example, transient ischemic attack (TIA));
• known hereditary or acquired tendency to arterial thromboembolism, such as hyperhomocysteinemia and antibodies to phospholipids (antibodies to cardiolipins, lupus anticoagulant);
• migraine with a history of focal neurological symptoms;
• high risk of arterial thromboembolism due to the presence of multiple risk factors or due to the presence of one serious risk factor, such as: diabetes mellitus with vascular complications; severe arterial hypertension; severe dyslipoproteinemia.

History of severe liver disease until liver function tests return to normal.

A benign or malignant tumor of the liver, now or in the past.

Suspected malignant tumors (for example, of the genitals or mammary glands), dependent on sex hormones.

Vaginal bleeding of unknown etiology.

Hypersensitivity to active substances or to any of the components of the preparation.

Mode of application

Method of use - oral.

The tablets should be taken in the order indicated on the package, at about the same time every day, with liquid as needed. The tablets should be taken continuously. Take one tablet daily for 28 consecutive days. Each next pack should be started the day after taking the last tablet from the previous pack. Withdrawal bleeding usually starts with the last pill in the pack and may not end when you start the next pill. In some women, bleeding begins after taking the first pills from a new package.

How to start taking the preparation "Klaira"

If no hormonal contraceptive was used (in the previous month), pills should be taken on the 1st day of the woman's natural cycle (that is, the first day of her menstrual bleeding).

When switching from another hormonal contraceptive for oral use, vaginal ring or transdermal patch. It is necessary to start using the preparation "Klaira" the next day after taking the last pill containing hormones, preliminary COC. In the case of using a vaginal ring or transdermal patch, you must start taking the preparation "Klaira" on the day the preparation is removed.

When switching from a progestogen method (an oral contraceptive containing only a progestogen, an injectable contraceptive, an implant) or an intrauterine system (IUD) with a progestogen).

A woman can switch to the use of Claira from an oral contraceptive containing only progestogen on any day (from an implant or IUD - on the day of removal, from an injection - on the day on which the next injection is to be made), but in any case on during the first 9 days of using the Klaira preparation, additional barrier contraceptives should be used.

After an abortion in the Ι trimester of pregnancy, you can immediately start using the preparation "Klaira". If the preparation is started, the woman does not require the use of additional methods of contraception.

After childbirth or abortion in the ΙΙ trimester of pregnancy. It is recommended to start taking the preparation on days 21-28 after childbirth or abortion in the ΙΙ trimester of pregnancy. With a later use, a woman should be advised of additional barrier methods of contraception during the first 9 days of taking the preparation. However, if intercourse has already taken place, before starting the use of COCs, it is necessary to exclude pregnancy or wait for the first menstrual period.

Application features

Pregnant

The preparation should not be used during pregnancy.

The use of COCs can affect lactation, since the amount and composition of milk can decrease and change. Therefore, the use of COCs is generally not recommended while the baby is still breastfeeding. Small amounts of contraceptive steroids and / or their metabolites can pass into breast milk and adversely affect the health of the baby.

Drivers

There was no effect on the ability to drive vehicles or other mechanisms in patients receiving the preparation "Klaira".

Overdose

There are no reports of serious consequences of an overdose of "Klaira".

Symptoms that can occur with an overdose of pills containing hormones: nausea, vomiting, in young girls - minor vaginal bleeding. There are no specific antidotes, and further treatment should be symptomatic.

Side effects

The most frequent adverse reactions that were observed with the use of the preparation "Klaira" as an oral contraceptive or as a treatment for heavy menstrual bleeding in women without organic pathology, who were prescribed oral contraception, were acne, discomfort in the mammary glands, headache, intermenstrual bleeding, nausea and body weight. Arterial and venous thromboembolism are serious adverse reactions.

Storage conditions

Store at a temperature not exceeding 30 ° C, out of the reach of children.

The shelf life is 5 years.

There are no reviews for this product.